Angiotensin Receptor-Neprilysin Inhibitor Therapy Reverses Pulmonary Hypertension in End-Stage Heart Failure Patients Awaiting Transplantation

Circ Heart Fail. 2020 Feb;13(2):e006696. doi: 10.1161/CIRCHEARTFAILURE.119.006696. Epub 2020 Feb 14.
No abstract available

Keywords: angiotensin; diuresis; ejection fraction; heart failure; hypertension.

Publication types

  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aminobutyrates / adverse effects
  • Aminobutyrates / therapeutic use*
  • Angiotensin II Type 1 Receptor Blockers / adverse effects
  • Angiotensin II Type 1 Receptor Blockers / therapeutic use*
  • Biphenyl Compounds
  • Drug Combinations
  • Heart Failure / complications
  • Heart Failure / diagnosis
  • Heart Failure / physiopathology
  • Heart Failure / surgery*
  • Heart Transplantation*
  • Hemodynamics / drug effects
  • Humans
  • Hypertension, Pulmonary / diagnosis
  • Hypertension, Pulmonary / drug therapy*
  • Hypertension, Pulmonary / etiology
  • Hypertension, Pulmonary / physiopathology
  • Neprilysin / antagonists & inhibitors*
  • Protease Inhibitors / adverse effects
  • Protease Inhibitors / therapeutic use*
  • Recovery of Function
  • Tetrazoles / adverse effects
  • Tetrazoles / therapeutic use*
  • Time Factors
  • Treatment Outcome
  • Valsartan
  • Waiting Lists*

Substances

  • Aminobutyrates
  • Angiotensin II Type 1 Receptor Blockers
  • Biphenyl Compounds
  • Drug Combinations
  • Protease Inhibitors
  • Tetrazoles
  • Valsartan
  • Neprilysin
  • sacubitril and valsartan sodium hydrate drug combination